J Cancer
2021; 12(17):5153-5163.
doi:10.7150/jca.54475 This issueCite
Research Paper
Development and Validation of a Nomogram based on cell growth-related Biomarkers for Oral Squamous Cell Carcinoma
Yanjie Shuai#, Yuansheng Duan#, Mengqian Zhou#, Kai Yue, Dandan Liu, Yan Fang, Yuxuan Wang, Yansheng Wu✉, Ze Zhang✉, Xudong Wang✉
Department of Maxillofacial & E.N.T oncology, Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin, China. #Co-first authors.
✉ Corresponding authors: Xudong Wang, E-mail: WXD.1133com; Ze Zhang, E-mail: zhangzeedu.cn; Yansheng Wu, E-mail: ywuedu.cn; Department of Maxillofacial and Otorhinolaryngology Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, Tianjin Cancer Institute, National Clinical Research Center of Cancer, Tianjin 300060, China.More
Citation:
Shuai Y, Duan Y, Zhou M, Yue K, Liu D, Fang Y, Wang Y, Wu Y, Zhang Z, Wang X. Development and Validation of a Nomogram based on cell growth-related Biomarkers for Oral Squamous Cell Carcinoma. J Cancer 2021; 12(17):5153-5163. doi:10.7150/jca.54475. https://www.jcancer.org/v12p5153.htm
Purpose: We aimed to develop a prognostic nomogram based on immunohistochemistry (IHC) biomarkers of patients with oral squamous cell carcinoma (OSCC).
Methods: A total of 294 patients were enrolled in the study. The least absolute shrinkage and selection operator (LASSO) Cox regression model was performed to develop a combined IHC score (IHCs) classifier.
Results: Five biomarkers, specifically c-Met, Vimentin, HIF-2α, VEGF-c, and Bcl-2 were extracted. Then, an IHCs classifier was developed, and patients were stratified into high- and low-IHCs groups. In the training cohort, the 5-year overall survival (OS) was 62.1% in low-IHCs group and 28.2% in high-IHCs group (P<0.001). The 5-year OS was 68.6% for the low-IHCs group and 28.4% for the high-IHCs group in the validation cohort (P<0.001). The area under the ROC curve (AUROC) of the combination of the IHCs classifier and TNM stage was 0.746 (95% CI: 0.658-0.833) in the training cohort and 0.735 (95% CI: 0.651-0.818) in the validation cohort, respectively.
Conclusions: The nomogram could effectively predict the prognosis for patients with OSCC and may be employed as a potential tool to guide the individual decision-making process.
Shuai, Y., Duan, Y., Zhou, M., Yue, K., Liu, D., Fang, Y., Wang, Y., Wu, Y., Zhang, Z., Wang, X. (2021). Development and Validation of a Nomogram based on cell growth-related Biomarkers for Oral Squamous Cell Carcinoma. Journal of Cancer, 12(17), 5153-5163. https://doi.org/10.7150/jca.54475.
ACS
Shuai, Y.; Duan, Y.; Zhou, M.; Yue, K.; Liu, D.; Fang, Y.; Wang, Y.; Wu, Y.; Zhang, Z.; Wang, X. Development and Validation of a Nomogram based on cell growth-related Biomarkers for Oral Squamous Cell Carcinoma. J. Cancer 2021, 12 (17), 5153-5163. DOI: 10.7150/jca.54475.
NLM
Shuai Y, Duan Y, Zhou M, Yue K, Liu D, Fang Y, Wang Y, Wu Y, Zhang Z, Wang X. Development and Validation of a Nomogram based on cell growth-related Biomarkers for Oral Squamous Cell Carcinoma. J Cancer 2021; 12(17):5153-5163. doi:10.7150/jca.54475. https://www.jcancer.org/v12p5153.htm
CSE
Shuai Y, Duan Y, Zhou M, Yue K, Liu D, Fang Y, Wang Y, Wu Y, Zhang Z, Wang X. 2021. Development and Validation of a Nomogram based on cell growth-related Biomarkers for Oral Squamous Cell Carcinoma. J Cancer. 12(17):5153-5163.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.